Drugs Causing Muscle Disease

Mor, Adam; Wortmann, Robert L.; Mitnick, Hal J.; Pillinger, Michael H.

doi:10.1016/j.rdc.2011.01.005

Cited by 21 publications

(25 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, because of some pathological disorders (e.g., AD, myasthenia gravis, amyotrophic lateral sclerosis), some patients may not possess the ability to behaviorally respond to pain. Furthermore, some medications such as statins, antiarrhythmic agents, corticosteroid agents, colchicine, chloroquine agents, immunomodulator agents, antiviral agents, antifungal/antibacterial agents, oncology drugs, gastrointestinal drugs, or neurological/psychiatric drugs may cause muscle weakness (reviewed in Mor, Wortmann, Mitnick, & Pillinger, 2011). …”

Section: Pain Assessment In Adults With Limited Ability To Communicatementioning

confidence: 99%

Pain Assessment in Hospitalized Older Adults With Dementia and Delirium

Paulson¹,

Monroe²,

Mion³

2014

J Gerontol Nurs

View full text Add to dashboard Cite

Pain can have negative effects leading to prolonged hospital stays. Determining the presence of uncontrolled and untreated pain in patients with cognitive impairments such as delirium, dementia, and delirium superimposed on dementia (DSD) is challenging. One tool commonly suggested for use in assessment of pain in older adults with cognitive impairment is the Pain Assessment In Advanced Dementia (PAINAD) scale. Proper use of the PAINAD scale as part of a comprehensive pain management plan can help reduce the likelihood of a patient experiencing unrecognized and untreated pain. Using an individual example, this article illustrates best practices in pain assessment and management for a woman experiencing DSD during an acute hospitalization.

show abstract

Section: Pain Assessment In Adults With Limited Ability To Communicatementioning

confidence: 99%

Pain Assessment in Hospitalized Older Adults With Dementia and Delirium

Paulson¹,

Monroe²,

Mion³

2014

J Gerontol Nurs

View full text Add to dashboard Cite

show abstract

“…The concomitant use of these two drugs may increase the risk of myotoxicity due to the pharmacokinetic interactions between these two medicines [8]. Furthermore, voriconazole was not concomitantly used with other drugs that can cause myotoxicity effects, such as corticosteroids, amiodarone, colchicine, cyclosporine, zidovudine, and vincristine [9]. Second, no other medical conditions that could cause myotoxicity were identi ed, such as idiopathic in ammatory myositis and hypothyroidism.…”

Section: Discussionmentioning

confidence: 99%

Muscle toxicity induced by intravenous voriconazole in a cryptogenic organizing pneumonia patient misdiagnosed as suspected pulmonary fungal infection

Wang

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Although voriconazole is a widely used azole antifungal agent in clinical practice, its side effect of muscle toxicity is extremely rare. The present study demonstrates an adverse effect of progressive myotoxicity induced by intravenous voriconazole in a cryptogenic organizing pneumonia patient misdiagnosed as suspected pulmonary fungal infection.Case presentation A 78-year-old male was admitted to our hospital due to recurrent cough and expectoration for four months. His previous chest CT scan indicated alveolar opacities and multiple cavitary nodules in the right lower lobe. Pulmonary fungal infection was considered due to weakly positive results of serum galactomannan and 1,3 β-D-glucan test,with no evidence of malignant tumor, tuberculosis, or Wegener's granulomatosis. The patient experienced diffuse myalgia with significantly elevated muscle enzymes after voriconazole administration for 13 days, and recovered uneventfully due to immediate voriconazole cessation and enhanced intravenous fluid infusion. Furthermore, the pulmonary cavitary nodules were consistent with the pathological findings of cryptogenic organizing pneumonia.Conclusions Voriconazole-associated myotoxicity should be considered when a patient presents with evidence of muscle injury during voriconazole administration. Morever, although invasive pulmonary fungal infection can often show multiple nodules with cavities in CT scan, the initiation of anti-fungal agents should be cautious before the pathological features of multiple cavitary nodules are identified, in order to avoid potential serious adverse events.

show abstract

“…Although muscle biopsy is not always necessary, it uncovers highly specific abnormalities, revealing a vacuolar myopathy with autophagic vacuoles [2,5] . Chronic RI, hepatopathy or diuretic use have been reported to be predisposing factors for this side effect at the usual dose range [2,4,7] . Moreover, it has been widely reported that co-administration of drugs that are metabolised by the CYP450 system can induce colchicine toxicity, including myopathy [3,5,7,8] .…”

Section: Discussionmentioning

confidence: 99%

“…Chronic RI, hepatopathy or diuretic use have been reported to be predisposing factors for this side effect at the usual dose range [2,4,7] . Moreover, it has been widely reported that co-administration of drugs that are metabolised by the CYP450 system can induce colchicine toxicity, including myopathy [3,5,7,8] . This fact is explained by the inhibition of CYP3A4 by other drugs metabolised by the same route, leading to increased levels of colchicine despite normal dosage.…”

Section: Discussionmentioning

confidence: 99%

Acute Colchicine-induced Neuromyopathy in a Patient Treated with Atorvastatin and Clarithromycin

Olmos-Martínez

Molina

Salas

et al. 2019

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Neuromyopathy is a rare side effect of chronic colchicine therapy, especially without renal impairment. Drugs interacting with colchicine metabolism through CYP3A4 can accelerate accumulation and toxicity. We describe a case of an interaction between atorvastatin, clarithromycin and colchicine resulting in acute neuromyopathy. LEARNING POINTS Colchicine has a narrow therapeutic window, and therefore, often produces side effects. Special caution should be adopted if patients with renal disease and concomitant medications are given colchicine. Before prescribing colchicine, the clinical history, including previous medications and conditions, should be carefully considered.

show abstract

Drugs Causing Muscle Disease

Cited by 21 publications

References 107 publications

Pain Assessment in Hospitalized Older Adults With Dementia and Delirium

Pain Assessment in Hospitalized Older Adults With Dementia and Delirium

Muscle toxicity induced by intravenous voriconazole in a cryptogenic organizing pneumonia patient misdiagnosed as suspected pulmonary fungal infection

Acute Colchicine-induced Neuromyopathy in a Patient Treated with Atorvastatin and Clarithromycin

Contact Info

Product

Resources

About